Dexcom stock fell 1.01 percent as RBC lifted its target
Dexcom stock fell 1.01% on October 2, 2026, despite RBC Capital raising its price target to USD 105 from USD 90 on October 1, maintaining an Outperform rating. The target increase is supported by the company's strong Q2 2026 revenue of USD 1.31 billion and adjusted earnings of USD 0.70 per share, surpassing estimates. Dexcom also reported significant expansion into the Type 2 diabetes market and its stock remains below its 52-week high but well above its low.
DexCom stock gets a higher RBC target before Q3 results
RBC Capital has raised its price target for DexCom (DXCM) from USD 90 to USD 105, maintaining an Outperform rating, ahead of the company's Q3 earnings report. Despite this positive analyst move, DexCom's stock closed down 1.01% at USD 85.36 on October 2, 2026, remaining below its 52-week high. The upcoming earnings report on October 29, 2026, will be crucial in assessing if Q2 revenue growth and the expansion into Type 2 diabetes are translating into continued earnings beats.
Dexcom announces Team Novo Nordisk partnership. Dexcom stock costs EUR 76.20
Dexcom has announced a partnership with Team Novo Nordisk, making Dexcom the team's official continuous glucose monitoring partner. The announcement comes as Dexcom's stock traded at EUR 76.20 in weekend trading, a slight increase from its previous close. This partnership follows Dexcom's release of its 2026 State of Type 2 Report, which identified key challenges in diabetes care.
Dexcom Hit With New Lawsuits Over G7 Monitor Failures
Dexcom is facing two new lawsuits alleging that its G7 continuous glucose monitors malfunctioned, causing severe medical emergencies in children. These recent filings bring the total number of cases against Dexcom by the firm Morgan & Morgan to 11, involving both G7 and G6 devices. The complaints highlight instances where the devices allegedly failed to accurately report blood glucose levels, leading to hospitalizations and life-threatening conditions.
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care
A Dexcom report highlights significant growth opportunities for Continuous Glucose Monitoring (CGM) in Type 2 diabetes care, particularly through increased awareness, improved reimbursement, and convergence with GLP-1 therapies. Despite high utility reported by existing users, awareness and access remain hurdles, while partnerships and new product developments from competitors like Abbott Laboratories and MiniMed underscore the competitive market. The report suggests three growth avenues for Dexcom: broader Type 2 adoption, integration with GLP-1 therapy, and continued expansion of CGM awareness.
DexCom (NASDAQ:DXCM): Strong Growth Paired With a High-Quality Technical Setup
DexCom (DXCM) is highlighted as a strong growth candidate with a high-quality technical setup, making it suitable for a screen that demands durable growth and a constructive chart. The company shows robust fundamental performance with significant EPS and revenue growth, strong profitability, and a healthy balance sheet, despite its valuation being above the S&P 500 average. Technically, DXCM exhibits a positive long-term trend with recent consolidation, offering defined support and resistance levels for potential breakout opportunities.
DEXCOM INC : RBC RAISES TARGET PRICE TO $105 FROM $90
RBC Capital has increased its price target for Dexcom Inc. (DXCM) to $105, up from the previous $90, while maintaining an "Outperform" rating on the stock. This adjustment reflects a positive outlook on the medical device company's financial prospects and market position.
RBC Raises Price Target on DexCom to $105 From $90, Keeps Outperform Rating
RBC has increased its price target for DexCom (DXCM) to $105 from $90, while maintaining an Outperform rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the medical equipment company specializing in continuous glucose monitoring systems.
Behavioral Patterns of DXCM and Institutional Flows
The article analyzes Dexcom Inc. (NASDAQ: DXCM) using AI models, highlighting a weak near-term sentiment despite long-term strength. It identifies a mid-channel oscillation pattern and presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. Key signals and multi-timeframe analysis are provided, indicating current price, resistance, and support levels for various horizons.
Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System
Tandem Diabetes Care (TNDM) stock rose 7.2% following the international launch of its Mobi insulin pump system in 12 countries, integrating with Dexcom G7 CGM and Control-IQ+ technology. This expansion supports Tandem's goal of broader international adoption and reinforces its focus on sensor interoperability and recurring supply revenue. Analysts project significant revenue and earnings growth for Tandem Diabetes Care, with a fair value indicating a potential 79% upside.
Under a preset trading plan, DexCom (DXCM) EVP Sadie Stern sells 2,565 shares.
DexCom (DXCM) EVP Sadie Stern sold 2,565 shares of common stock at $86.15 per share on September 28, 2026, under a Rule 10b5-1 plan adopted earlier that year. Following the sale, her directly held position is 123,478 shares, which includes 71,903 unvested restricted stock units with vesting dates extending through March 8, 2029. This transaction is considered to have a moderate impact and negative sentiment, according to Rhea-AI.
Abbott Laboratories (ABT) stock price, news, quote and history
This page provides an overview of Abbott Laboratories (ABT) stock, including its current price, recent news headlines, dividend information, and performance metrics. As of September 29, 2026, ABT was trading at 100.95 USD, with a slight dip after hours, and had announced a cash dividend of $0.63. The news section highlights recent analyst opinions and company-specific events affecting ABT and related healthcare stocks.
Dexcom stock last trades at USD 86.68 on September 28, 2026
Dexcom stock closed at USD 86.68 on September 28, 2026, marking a 0.07 percent increase from its previous close. The company announced the release of its 2026 State of Type 2 Report and a new partnership with Team Novo Nordisk, which designates Dexcom as the official continuous glucose monitoring partner for the professional cycling team.
Dexcom Data Points to a CGM Awareness Gap, and Room to Grow
Dexcom's new "State of Type 2 Report" reveals a significant awareness gap regarding continuous glucose monitoring (CGM) despite its proven benefits, especially for Type 2 diabetes patients. The report highlights that while healthcare professionals recognize CGM's value, patient familiarity and access remain limited due to factors like coverage and reimbursement. Additionally, Dexcom has partnered with Team Novo Nordisk, an all-diabetes professional cycling team, to further raise awareness and demonstrate CGM's effectiveness in real-world, demanding conditions.
Tandem Diabetes Expands Insulin Delivery System to 12 New Countries
Tandem Diabetes Care (TNDM) has expanded the availability of its Mobi automated insulin delivery system to 12 new countries. The article indicates that full access to this news requires a premium subscription.
The Insider Report: The Leaders Have Taken Off
The article, "The Insider Report: The Leaders Have Taken Off," discusses the current market environment where the Nasdaq and S&P 500 have reached new highs, driven by a selective group of leading stocks. It highlights three specific companies—Pattern Group (PTRN), Zai Lab (ZLAB), and DexCom (DXCM)—providing detailed analysis of their business models, financial performance, and growth catalysts, along with bullish action plans for each. The report also touches on broader market concerns like breadth, inflation data dependency, and the outperformance of technology and crypto assets.
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte, Inc. (Nasdaq: HUMA) has appointed Scott Coward and Paul Kuznik to its Board of Directors, enhancing its expertise in commercialization, enterprise leadership, and global operations. These additions are strategic as the company expands its Symvess® launch and prepares for the commercial launch of its ATEV in dialysis access. Both new board members bring extensive experience in the life sciences and medical technology sectors, which will be crucial for Humacyte's anticipated U.S. market launch in dialysis and its broader regenerative medicine initiatives.
DexCom stock reports 13.1 percent revenue growth at USD 86.62
DexCom reported strong Q2 2026 results, with adjusted EPS of USD 0.70 and revenue of USD 1.31 billion, exceeding analyst expectations. The company achieved 13.1 percent year-over-year revenue growth due to the adoption of its continuous glucose monitoring systems. Analysts, like Truist, have raised price targets, reflecting confidence in DexCom's continued execution, despite the stock trading below its 52-week high.
MEDS Stock Rockets As DataMEDS AI Bets Big On Cancer Diagnostics
DataMeds AI Inc. (MEDS) stock has surged by 25.4% following its acquisition of Helomics, an AI cancer diagnostics lab, and a settlement that removed significant liabilities. The company is pivoting towards oncology diagnostics and has engaged in new partnerships, fueling speculative trading interest despite its early-stage and unprofitable financial status. Traders are closely watching MEDS due to its recent fundamental reset and multiple narrative catalysts.
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Tandem Diabetes Care announced the international launch of its Tandem Mobi automated insulin delivery system in twelve countries, including Belgium, Germany, and the UK. This system, powered by Control-IQ+ technology, is the world's smallest durable insulin pump and integrates with the Dexcom G7 continuous glucose monitoring system. The company plans further expansion of availability in additional countries.
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
Dexcom released its "State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" ahead of the EASD 2026 conference, highlighting the urgent need to bridge the gap between continuous glucose monitoring (CGM) technology's proven impact and its limited awareness and access for people with Type 2 diabetes. The report underscores that while healthcare professionals recognize CGM's benefits, barriers like awareness, coverage, and reimbursement hinder adoption. Additionally, Dexcom announced a partnership with Team Novo Nordisk, the all-diabetes professional cycling team, to promote education and awareness of glucose insights.
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
Dexcom released its "State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" during EASD 2026, highlighting the urgent need to bridge the gap between CGM's proven benefits and the millions with Type 2 diabetes who lack awareness or access. The report identifies health literacy, technology literacy, and systemic access as key challenges. Additionally, Dexcom announced a partnership with Team Novo Nordisk, the all-diabetes professional cycling team, to become their official continuous glucose monitoring partner, reinforcing its commitment to advancing Type 1 diabetes care and awareness.
IT Stocks In Focus: TCS, Mphasis Defy Nifty IT Weakness; Citi Cuts TCS Target Price, Maintains 'Sell'
The Nifty IT index fell 0.84% due to pressure on IT stocks, with Wipro, Persistent Systems, LTIMindtree, Infosys, and TCS leading the decline. Citi maintained a 'Sell' rating on TCS and lowered its target price to Rs 1,875 from Rs 2,040, citing persistent challenges in the IT services sector and a rerating across IT stocks. Despite marginal revisions to FY27-FY29 estimates, Citi's 'Sell' recommendation reflects caution regarding the sector's growth and valuation outlook.
FriskaAi and Dexcom Enter CGM Data Integration Agreement
FriskaAi and Dexcom have announced an agreement to integrate data from Dexcom G7 and G6 Continuous Glucose Monitoring (CGM) Systems into the FriskaAi platform. This integration will allow FriskaAi's AI-powered healthcare platform to support physicians and patients with personalized care management for diabetes and other chronic diseases. The partnership aims to empower patients and provide clinicians with actionable insights for proactive and preventive care strategies.
Dexcom stock slips 2.01 percent ahead of the open
Dexcom stock declined by 2.01 percent, closing at USD 87.73 on September 24, 2026, underperforming the Nasdaq Composite which rose slightly. The stock's closing price was USD 4.86 below its 12-month high. Truist Financial maintained a Buy rating with a USD 102.00 price target for Dexcom.
How Lingo Partnership Will Impact Abbott Stock (ABT)
Abbott Laboratories recently announced a partnership with Berry Street, integrating its Lingo glucose monitor with virtual nutrition coaching, alongside the expansion of its Volt Pulsed Field Ablation System for cardiac procedures. This collaboration, especially with Lingo, aims to extend glucose tracking beyond traditional diabetes care, influencing Abbott's long-term investment narrative by pushing into everyday health use cases, though near-term earnings risks persist due to legal and regulatory issues in its Nutrition arm. While the partnership supports Abbott's operational goals and potential revenue growth, its impact on the company's financial forecasts and overall fair value remains a subject of varied analyst opinions.
DexCom stock trades below its 52-week high as Truist lifts target
DexCom's stock is trading below its 52-week high despite Truist raising its price target from $93 to $102. The company reported strong Q2 revenues of $1.31 billion, a 13.1% year-over-year increase, and exceeded analyst estimates for both revenue and earnings per share. This performance provides a solid operational basis for the stock, and the market is now looking to see if continued operating growth can close the gap between the current share price and the new target.
Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating
Truist has lowered its price target for Tandem Diabetes Care (TNDM) from $31 to $28 but maintained a "Buy" rating on the stock. This adjustment comes amidst various analyst actions, including price target changes and rating adjustments from other firms like RBC, Deutsche Bank, and UBS. The article also provides recent news and financial updates related to Tandem Diabetes Care.
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?
Insulet Corporation (PODD), a medical device company specializing in insulin delivery systems, has experienced a significant stock decline, underperforming the iShares U.S. Medical Devices ETF (IHI) and its rival, DexCom (DXCM). This underperformance is attributed to commercial friction in its Type 2 diabetes segment, lower-than-expected user retention rates, and increased competition, despite beating Q2 earnings expectations. Analysts, however, maintain a "Moderate Buy" rating with a potential upside.
Dexcom stock falls 1.1 percent ahead of the open
Dexcom stock fell 1.1 percent on the Nasdaq on September 23, 2026, closing at USD 87.93, while the Nasdaq Composite dropped 1.13 percent. The decline was influenced by rising Treasury yields, increased oil prices, and stronger economic data. Upcoming US economic data releases, including unemployment claims and new home sales, are expected to further impact the market.
GlucoGuard, a Division of American Diversified Holdings (ADHC), Has Completed an Investors Deck Focused on Funding Research Required for FDA Approval
GlucoGuard, a division of American Diversified Holdings (ADHC), has finalized an investors deck to secure funding for FDA approval research. The company has also successfully completed a revised Level 2 App integration through Dexcom's Developer Program, in collaboration with UC Irvine's MADO program. GlucoGuard is developing an innovative nocturnal glucose monitoring and delivery system that uses AI to predict and mitigate hypoglycemic events, aiming to revolutionize diabetes management in a multi-billion dollar industry.
Stoneridge's incoming engineering leader brings more than 25 years in automotive electronics.
Stoneridge Inc. has appointed Uwe Brandenburg as Global Vice President, Engineering & Innovation, effective November 2, 2026. Brandenburg brings over 25 years of experience in automotive electronics and will lead Stoneridge's global engineering organization, focusing on product development and innovation in vision, safety, vehicle intelligence, and connectivity. His expertise is expected to accelerate the company's technology roadmap and strengthen its competitive position.
DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer
DexCom (DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer, a move seen as prioritizing continuity in leadership for global operations and quality. This aligns with DexCom's focus on execution for type 2 and prediabetes adoption, international expansion, and the ramp-up of its Ireland plant. Investors should monitor operational and margin commentary regarding the Ireland facility and global supply chain in future results to assess the impact of these changes.
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history
This article provides a comprehensive overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, historical data, financial performance, and analyst insights. It details the company's operations across companion animal, water quality, and livestock segments, highlighting its diverse product and service offerings in diagnostics and research. The report also includes key financial metrics, performance comparisons against the S&P 500, and analysts' price targets.
DexCom Inc. stock underperforms Wednesday when compared to competitors
DexCom Inc. (DXCM) stock fell 2.01% on Wednesday, closing at $87.73, while the broader market also saw declines with the S&P 500 and Dow Jones Industrial Average dropping. The company's stock is now 5.25% below its 52-week high reached on August 24th. This performance indicates DexCom underperformed its competitors during the trading session.
GlucoGuard, a Division of American Diversified Holdings (ADHC), Has Completed an Investors Deck Focused on Funding Research Required for FDA Approval
GlucoGuard, a division of American Diversified Holdings (ADHC), has finalized an investor deck to secure funding for research necessary for FDA approval of its nocturnal glucose monitoring system. The company is actively engaging with institutional investors and has also completed an updated Level 2 App integration with Dexcom's Developer Program. GlucoGuard's technology aims to prevent hypoglycemic episodes during sleep through AI-powered continuous monitoring and glucose delivery.
American Diversified Holdings Corporation (ADHC) Seeks Funding; Advances Dexcom App Integration
American Diversified Holdings Corporation (ADHC) is actively seeking funding for its GlucoGuard product, having completed an investor deck and advanced its Dexcom app integration to Level 2. A spinoff is under discussion during financing talks, and the company has stated that a reverse split is not being considered. These steps are aimed at funding research and development towards FDA approval.
Medtronic plc (MDT) latest stock news and headlines
This article provides recent news and financial data for Medtronic plc (MDT), including its latest stock performance, dividend announcement, and various headlines from different financial news sources. It highlights several market forecasts related to medical devices and wearable biosensors, along with news about FDA clearances for Medtronic's Hugo™ RAS system.
Dexcom stock heads into the open after Nasdaq gains 0.45 percent
Dexcom stock opened at USD 89.17 on September 22, 2026, while the Nasdaq Composite increased by 0.45 percent to 27,244.28. The stock's 12-month range was USD 54.11 to USD 92.59, and it had a market capitalization of USD 33.65 billion. MarketBeat identified DexCom as a medical stock to watch due to its trading volume and analyst interest.
Dexcom stock holds near its yearly high after Q2 growth
Dexcom stock is trading near its yearly high after reporting strong Q2 2026 growth, with revenue increasing by 13.1% to $1.31 billion and exceeding analyst estimates. Truist Securities maintained its "Buy" rating and raised its price target to $102. The stock's market capitalization stands at $33.65 billion, and it is trading above its 50-day and 200-day moving averages.
State Street Corp Purchases 1,658,301 Shares of Medtronic PLC $MDT
State Street Corp increased its stake in Medtronic PLC by 2.7%, purchasing an additional 1.66 million shares, bringing its total holdings to 63.4 million shares valued at approximately $5.0 billion. This comes as Medtronic reported stronger-than-expected quarterly results with an EPS of $1.45 and revenue of $9.76 billion, a 13.7% year-over-year increase. Despite an executive selling shares, analysts maintain a "Moderate Buy" consensus with a target price of $103.92, and the company also declared a quarterly dividend of $0.72 per share.
Penumbra, Inc. (PEN) Stock Analysis: Evaluating A 13.93% Upside Potential
Penumbra, Inc. (PEN) is a medical devices company with a market cap of $12.51 billion, showing robust revenue growth and strong profitability. Analysts are cautiously optimistic, with an average target price suggesting a 13.93% upside potential. The company's strategic focus on innovation and expanding product offerings make it an intriguing opportunity for investors looking for capital appreciation in the healthcare sector.
DexCom, Inc. (DXCM) stock price, news, quote and history
This page provides comprehensive financial information for DexCom, Inc. (DXCM), including its current stock price, historical data, and key financial metrics. It details the company's market performance, valuation measures, profitability, and allows for comparison with similar companies in the industry. The article also provides the stock's performance during regular and overnight trading sessions.
Dexcom (NASDAQ: DXCM) legal chief sells shares, keeps 99,885-share stake
Michael Jon Brown, EVP and Chief Legal Compliance Officer at Dexcom (DXCM), sold 1,700 shares of common stock for approximately $142,868 on September 15, 2026, under a Rule 10b5-1 trading plan. Following this transaction, Brown directly holds 99,885 shares, including unvested restricted stock units and shares from an employee stock purchase plan. The sale was a routine disposition as part of a pre-established plan.
DEXCOM INC : TRUIST SECURITIES RAISES TARGET PRICE TO $102 FROM $93
Truist Securities has increased its target price for Dexcom Inc. (DXCM.O) to $102, up from the previous $93. This adjustment reflects the analyst's updated outlook on the company's financial prospects. The information was reported by Reuters.
Medtronic Raises Guidance Again as Heart Device Demand Surges
Medtronic has raised its fiscal 2027 profit and revenue outlook for the second time, driven by strong demand for cardiovascular devices and double-digit growth across all major business segments. The company reported first-quarter revenue of $9.76 billion and adjusted earnings per share of $1.45, both exceeding analyst expectations. While new partnerships and product launches fuel optimism, Medtronic faces challenges including tariff headwinds and uncertainty surrounding the potential separation of its diabetes business.
Dexcom (NASDAQ: DXCM) director’s trust sells 8,089 shares in preset plan
Dexcom director Nicholas Augustinos, through a revocable trust, sold a total of 8,089 shares of Dexcom common stock across two transactions on September 14 and 15, 2026, at prices around $84 per share. These sales were executed under a pre-established Rule 10b5-1 trading plan adopted on June 10, 2026. Augustinos still retains 5,575 unvested restricted stock units directly.
Dexcom Insider Sold Shares Worth $679,769, According to a Recent SEC Filing
A recent SEC filing revealed that an insider at Dexcom sold shares totaling $679,769. The article, published on September 16, 2026, by MT Newswires, provides this financial detail without further elaboration, as the content is reserved for members. This transaction follows other insider sales and company announcements from Dexcom, including a CFO promotion and other significant appointments.
Dexcom gives CFO Jereme Sylvain expanded role
Dexcom has promoted CFO Jereme Sylvain to the additional role of chief operating officer. This move fills a vacancy created by the previous COO, Jake Leach, becoming CEO. Sylvain will oversee global operations, focusing on alignment, speed, and accountability, and will play a key role in the company's international expansion and the rollout of its 15-day glucose sensor.
VERI Jumps As Veritone Lands Major UK Policing Deal
Veritone Inc. (VERI) experienced a significant stock surge of 21.55% following news of its major AI expansion, specifically a deal with UK policing for digital forensics. Despite this positive development, the company faces structural financial weaknesses, including deeply negative profitability and unsustainable cash burn, leading to a reduced price target from Needham. The article highlights that while the UK framework win provides a clear growth lane, its monetization will be gradual, and traders should approach VERI as a high-risk AI stock.
